Replies to post #27631 on MindMaze Therapeutics Holding (RLFTF)

[aGuyUS]

@nelskof

The PhaseBio VIP Derivative is made so it's half life is increased. the theory being increase half life and Increase bioavailability of the hormone to fight covid.

The likely issue with PhaseBio's drug is the delivery being subcutaneous (Subq) In patients infected with Covid and suffering from O2 deprivation they don't want walk or move. SUBQ relies on the lymphatic system for delivery, This system is not under pressure like the arterial blood portion of the the peripheral circulatory system.

Without the patient wanting to move about....the lymphatic fluid doesn't move... without movement of lymphatic fluid, no delivery of VIP...no delivery of VIP but no side effects either... One is a plus and good to know the other is good to know as well.. You have to deliver VIP directly to the lungs as in IV....Dr. Javitt even said he wouldn't use Inhalers on Severe/critical because the chace was you needed a more direct delivery that being the arterial system of the Blood stream

[Uncle Gee Gee]

True "we only know of 21 patients"... but perhaps these couple unofficial observations can help put some additional background to it...

- My understanding is the fda typically looks for a pval of P=<.001 (or maybe it was only P=<.01 if I recall - and I'm hoping someone can point us to an official source). Albeit a small sample, the 21 patients came in at P=<.0001, so quite a bit better.

- Remember when Javitt was discussing the 9-fold efficacy over soc, he also stated that there were more data they're seeing from the open label study and it is in line with the results from the 21. He seemed pretty certain the results are not the worlds largest placebo effect.

Sorry... I don't have all my facts and sources in front of me, but these are the points I do consider above the official info... given it comes from Javitt.

[r_deckard]

Here Dr. Javitt talks about the difference between RLF-100 and other synthentic VIPs